November 29, 2016 - By Louis Casey · 0 Comments
The stock of Compugen Limited (NASDAQ:CGEN) registered an increase of 5.72% in short interest. CGEN’s total short interest was 1.60M shares in November as published by FINRA. Its up 5.72% from 1.52 million shares, reported previously. With 71,300 shares average volume, it will take short sellers 23 days to cover their CGEN’s short positions. The short interest to Compugen Limited’s float is 3.33%. The stock last traded at $6.05 per share. It is down 12.06% since April 26, 2016 and is downtrending. It has underperformed by 17.32% the S&P500.
Compugen Ltd. is a therapeutic discovery company. The company has a market cap of $303.35 million. The Firm focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. It currently has negative earnings. The Company’s pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.
Out of 5 analysts covering Compugen (NASDAQ:CGEN), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Compugen has been the topic of 8 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The stock has “Outperform” rating given by Cowen & Co on Thursday, October 15. Zacks upgraded the shares of CGEN in a report on Friday, August 21 to “Sell” rating. Oppenheimer maintained the shares of CGEN in a report on Wednesday, August 5 with “Buy” rating. The stock of Compugen Ltd. (USA) (NASDAQ:CGEN) earned “Outperform” rating by FBR Capital on Thursday, October 15. As per Wednesday, August 5, the company rating was maintained by MLV. The firm has “Hold” rating by Zacks given on Wednesday, September 2. The firm earned “Market Outperform” rating on Wednesday, March 9 by JMP Securities.
Compugen Ltd. (Compugen), incorporated on February 10, 1993, is a therapeutic discovery company. The Firm focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. The Company’s business model includes entering into collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements. It utilizes integrated infrastructure of scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of drug target candidates, which are then experimentally validated. The Firm has established the Pipeline Program, consisting of targets and product candidates for applications in oncology and immunology, based on immune checkpoint candidates discovered during its first focused discovery program.
More notable recent Compugen Ltd. (USA) (NASDAQ:CGEN) news were published by: Prnewswire.com which released: “Dr. Elliott Sigal Joins Compugen Ltd. as Strategic Advisor and Prof. Drew …” on April 06, 2016, also Businesswire.com with their article: “Compugen Discloses Antibody Drug Conjugate Program Results at the World ADC …” published on October 19, 2015, Prnewswire.com published: “Compugen to Host R&D Day on December 7, 2016 in New York” on November 03, 2016. More interesting news about Compugen Ltd. (USA) (NASDAQ:CGEN) were released by: Prnewswire.com and their article: “Compugen Presents Results for CGEN-15029 Immuno-Oncology Therapeutic Program” published on February 29, 2016 as well as Prnewswire.com‘s news article titled: “Compugen Discloses Lead Therapeutic Candidate for CGEN-15029 Immuno-Oncology …” with publication date: June 22, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Louis Casey